Initial admission to the Official List

Initial admission to the Official List GlobeNewswire December 08, 2025 Advertisement THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM CANADA, SWITZERLAND OR INDIA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. Amsterdam, The Netherlands 8 December 2025 The Magnum Ice […]

EpiEndo Pharmaceutical’s ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients

EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients GlobeNewswire December 08, 2025 ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients Glasmacinal, a novel macrolide, was well tolerated and reduced neutrophilic inflammation in COPD patients. Glasmacinal had no detectable impact on the

SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS GlobeNewswire December 08, 2025 SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS December 8, 2025 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the third quarter 2025 interim dividend, which was

AI Agents to Power 1,000% More Customer Interactions for Enterprises Globally by 2027

AI Agents to Power 1,000% More Customer Interactions for Enterprises Globally by 2027 GlobeNewswire December 08, 2025 BASINGSTOKE, United Kingdom, Dec. 08, 2025 (GLOBE NEWSWIRE) — A new study by global tech strategists Juniper Research has found that the number of customer interactions automated by AI agents will grow from 3.3 billion interactions in 2025

Pulsar Helium Reports Pressurised Gas Encounter at Jetstream #5 and Down-Hole Testing Conducted at Jetstream #3 and #4

Pulsar Helium Reports Pressurised Gas Encounter at Jetstream #5 and Down-Hole Testing Conducted at Jetstream #3 and #4 GlobeNewswire December 08, 2025 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE

Bowman Acquires RPT Alliance, Broadens Energy Engineering to Include Utility-Scale Power Generation for Data Centers and Industrial Facilities

Bowman Acquires RPT Alliance, Broadens Energy Engineering to Include Utility-Scale Power Generation for Data Centers and Industrial Facilities High-growth acquisition adds specialized natural gas transmission and power generation engineering as electrification imperatives accelerate nationwide GlobeNewswire December 08, 2025 RESTON, Va., Dec. 08, 2025 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering,

EQT agrees to sale of shares in Galderma Group AG to L’Oréal S.A.

— C. 24 million shares to be sold Further to previous announcements, an affiliate of the funds known as EQT VIII (“EQT”) is pleased to announce it has signed an agreement to sell c. 24 million shares in Galderma Group AG (SIX: GALD) (the “Company”) to L'Oréal S.A at an undisclosed premium (the “Sale”). Out

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstBaxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased

GC Biopharma Ships First Doses of World’s First Recombinant Anthrax Vaccine, ‘BARYTHRAX inj.’

First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly developed by the Korea Disease Control and Prevention Agency

Scroll to Top